Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,463 total articles

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Ultragenyx Pharmaceutical announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. The PRV was granted following FDA approval of Genelycos™, a treatment for glycogen storage disease type Ia. The sale is expected to provide non-dilutive capital to advance Ultragenyx's pipeline and support pr…

OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company’s Real World Data Footprint into Korea and the Asia Pacific Region

OneMedNet Signs Mediplexus as its 11th Channel Partner, Expanding the Company’s Real World Data Footprint into Korea and the Asia Pacific Region

OneMedNet Corporation announced a strategic partnership with Mediplexus, a Korean healthcare data company, to distribute its U.S.-sourced Real World Data in Korea and the broader Asia Pacific region. This agreement marks OneMedNet's 11th channel partner and aims to broaden collaborative data applications for Korean biopharma, medtech, and medical A…

Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics

Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics

Progyny, Inc., a leader in women's health and family-building solutions, announced that its current annual selling season is pacing to a record level with an expected addition of 1.2 million new covered lives in the first half of 2027. The company's fertility solutions address rising medical cost inflation by offering employers programs that improv…

SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture

SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture

SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs and further its subsidiary CliniQuantum, announced a successful demonstration of a quantum-enabled GPU-accelerated platform that analyzed over 7 billion potential three-gene combinations in real-world clinical data. Utilizing a single NVIDIA T4 GPU, their platform achieved approxi…

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

SeaStar Medical received FDA Breakthrough Device Designation for its Selective Cytopheretic Device (SCD) therapy to treat hyperinflammation in adult patients with sepsis or septic conditions. This designation accelerates development and review processes, marking the seventh breakthrough designation for the SCD platform across multiple indications. …

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA Biotechnology announced completion of patient enrollment in Part C of its Phase 2 THIO-101 trial and achieving 65% enrollment in its pivotal Phase 3 THIO-104 trial investigating ateganosine combined with checkpoint inhibitors for treatment of advanced non-small cell lung cancer (NSCLC). Interim Phase 2 data show high disease control rates sign…

FuelCell Energy Announces Chief Financial Officer Transition

FuelCell Energy Announces Chief Financial Officer Transition

FuelCell Energy, Inc. announced a planned transition in its CFO position with Michael Bishop stepping down after 15 years and Matthew Latino succeeding him. The company reaffirmed its target to achieve positive Adjusted EBITDA in Q4 fiscal 2027, contingent on production increases and backlog conversion. FuelCell Energy is focused on scaling manufac…

EXL schedules third quarter 2026 financial results conference call

EXL schedules third quarter 2026 financial results conference call

ExlService Holdings, Inc., a global data and AI company, will release its financial results for the third quarter ended September 30, 2026, on October 27, after market close. The company will host a conference call on October 28 featuring executives discussing operational and financial outcomes. EXL serves multiple industries including insurance, h…

Safe Pro Expects Record 2,300% Revenue Growth in Q3 2026 Driven by Multiple Government Contracts for AI-Powered Threat Detection and Mapping

Safe Pro Expects Record 2,300% Revenue Growth in Q3 2026 Driven by Multiple Government Contracts for AI-Powered Threat Detection and Mapping

Safe Pro Group Inc., a U.S.-based AI-enabled defense and security solutions company, announced preliminary expectations of a 2,300% year-over-year revenue growth in Q3 2026, driven by multiple U.S. Army and Air Force subcontracts. The company's innovative AI threat detection and battlefield mapping technology is gaining traction with government age…

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

Kyverna Therapeutics announced presentation of encouraging one-year data from its pivotal Phase 2 trial of miv-cel, a CD19 CAR T-cell therapy, in stiff person syndrome (SPS), showing sustained clinical benefit and a favorable safety profile. Additionally, updated positive Phase 1 data in progressive multiple sclerosis (MS) will be shared. These res…

Erin Schaefer, Former Google/YouTube Senior Executive, Joins Roundtable Board to Help Guide Premium-Media OS Growth

Erin Schaefer, Former Google/YouTube Senior Executive, Joins Roundtable Board to Help Guide Premium-Media OS Growth

Roundtable (NASDAQ: RTB), an AI and DeFi-powered Enterprise Media Operating System, announced Erin Schaefer, former senior executive at Google, YouTube, and Niantic Games, has joined its Board of Directors. Schaefer brings extensive experience in scaling multi-billion-dollar commercial media businesses and strategic leadership in technology and bra…

Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home

Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home

Pacira BioSciences and the Caregiver Action Network conducted a national survey revealing that family caregivers often feel unprepared to manage postsurgical pain and recovery at home. The survey highlights gaps in communication about pain management options, especially non-opioid therapies, and underscores caregivers’ need for clearer, practical i…

WillScot Elects Donald Slager to Board of Directors

WillScot Elects Donald Slager to Board of Directors

WillScot Holdings Corporation has elected Donald Slager, former CEO of Republic Services, to its Board of Directors as an independent director. Slager brings extensive experience in corporate governance and leadership during transformative periods, expected to support WillScot's long-term strategic objectives. He joins key committees to aid governa…

Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Esperion Therapeutics has reached a settlement agreement with Renata Limited preventing the marketing of generic versions of its cholesterol-lowering drugs NEXLETOL and NEXLIZET in the US until April 19, 2040, reinforcing its patent protection. Ongoing litigations with other generic filers continue. Esperion, wholly owned by ARCHIMED, focuses on ca…

Mobilicom to Unveil New Solution and Showcase Cybersecure Portfolio at AUSA 2026; Company to Present at ThinkEquity Investor Conference

Mobilicom to Unveil New Solution and Showcase Cybersecure Portfolio at AUSA 2026; Company to Present at ThinkEquity Investor Conference

Mobilicom Limited announced its participation at AUSA 2026 where it will showcase a new cybersecure communication solution designed for autonomous defense operations, addressing increasing data demands. Additionally, the company will present its business and growth opportunities in the drone, robotics, and defense sectors at the ThinkEquity investo…